Peyton Howell

Peyton Howell is Chief Executive Officer of Parexel and a member of the company’s Board
of Directors. She has more than 30 years of pharma services and healthcare industry experience and currently represents the company as Chairperson of the Association of Clinical Research Organizations (ACRO).

Peyton served most recently as Chief Operating and Growth Officer responsible for Parexel’s operational delivery, strategy and growth. From 2018 to 2022 she was the company’s Chief Commercial and Strategy Officer, implementing its patient-focused strategy and launching its Biotech business unit. During her tenure Peyton has made a significant impact in growing Parexel’s customer relationships, delivering strong growth in gross new business awards during a period of significant change in the life sciences industry.

Peyton’s healthcare industry experience includes senior leadership positions with AmerisourceBergen (now Cencora), a Fortune 20 company, most recently as President for Health Systems and Specialty Care Solutions, a $50 billion business unit. Prior to AmerisourceBergen, she was a founder of Lash Group, growing the company from an early innovator of patient access services to nearly 5,000 employees and serving as President for nearly 10 years following its acquisition by AmerisourceBergen.

Peyton serves on the Board of Directors of Tandem Diabetes Care (NASDAQ: TNDM), a medical device manufacturer. She holds a Master of Healthcare Administration from The Ohio State University and a Bachelor of Arts in Health Communications from the University of Illinois. In 2022, Peyton was recognized with PharmaVoice’s highest distinction as a Red Jacket honoree, which distinguishes an elite group of leaders viewed as the most inspiring in the life sciences industry.